0000950170-24-077410.txt : 20240625 0000950170-24-077410.hdr.sgml : 20240625 20240625170502 ACCESSION NUMBER: 0000950170-24-077410 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240621 FILED AS OF DATE: 20240625 DATE AS OF CHANGE: 20240625 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lister Troy CENTRAL INDEX KEY: 0002023489 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40489 FILM NUMBER: 241069786 MAIL ADDRESS: STREET 1: C/O VERVE THERAPEUTICS, INC. STREET 2: 201 BROOKLINE AVENUE, SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Verve Therapeutics, Inc. CENTRAL INDEX KEY: 0001840574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 824800132 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: (978) 501-3026 MAIL ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 4 1 ownership.xml 4 X0508 4 2024-06-21 false 0001840574 Verve Therapeutics, Inc. VERV 0002023489 Lister Troy C/O VERVE THERAPEUTICS, INC. 201 BROOKLINE AVENUE, SUITE 601 BOSTON MA 02215 false true false false Chief Scientific Officer false Stock Option (right to buy) 5.29 2024-06-21 4 A false 32000 0 A 2034-06-20 Common Stock 32000 32000 D The option was granted on June 21, 2024. 25% of the shares underlying the option will vest on June 21, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until June 21, 2028. /s/ Andrew Ashe, as Attorney-in-Fact for Troy Lister 2024-06-25